Drug intelligence / Profile preview

SCT-h002

Development stage: Preclinical
Lead developer: SymbioCellTech
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intraperitoneal

Overview

**SCT-h002** is a feasibility-stage **Neo-iPSC cell therapy** being developed by SymbioCellTech for **type 1 diabetes mellitus**. The program uses Neo-iPSC technology, described by the developer as a combination of induced pluripotent stem cells and mesenchymal stem cells. No molecular target, cell-product composition, manufacturing process, route of administration, or clinical protocol details have been publicly specified.

Beyond the preview

Go deeper on SCT-h002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT-h002.

Explore the full profile